Health Care • Biotechnology: Pharmaceutical Preparations
$275.20 ▲ +4.16
(+1.54%)
MKT CAP: $662.49B • VOL: 6.02M
52W L $185 52W H $282
JNJ // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-28 | FY 2024
FILED 2024-12-29 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $94.19B | $88.82B | $85.16B |
| YoY Revenue Growth % | +6.0% | +4.3% | — |
| Gross Profit | $63.94B | $61.35B | $37.47B |
| Gross Margin % | 67.9% | 69.1% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $31.63B | $16.60B | $41.48B |
| Operating Margin % | 33.6% | 18.7% | 48.7% |
| Net Income (GAAP) | $26.80B | $14.07B | $35.15B |
| EBITDA (Normalized) | $35.49B | $20.14B | $44.55B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $24.53B | $24.27B | $22.79B |
| Capital Expenditures (CapEx) | $4.83B | $4.42B | $3.83B |
| Free Cash Flow (FCF) | $19.70B | $19.84B | $18.96B |
| FCF Margin % | 20.9% | 22.3% | 22.3% |
| Return on Invested Capital (ROIC %) | 24.7% | 16.8% | 14.9% |
| Cash & Short-Term Equivalents | $19.71B | $24.11B | $40.08B |
| Total Debt (Short + Long Term) | $39.44B | $30.65B | $85.26B |
| Total Stockholders' Equity | $81.54B | $71.49B | $174.90B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR JNJ.